EE540 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in the United Kingdom
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.805
https://www.valueinhealthjournal.com/article/S1098-3015(23)03935-9/fulltext
Title :
EE540 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in the United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03935-9&doi=10.1016/j.jval.2023.09.805
First page :
Section Title :
Open access? :
No
Section Order :
10292